Risk of liver cancer in HFE-hemochromatosis

Authors/Creators

John K. Olynyk, Edith Cowan UniversityFollow
Grant A. Ramm

Abstract

Atkins et al conducted a study examining the community incidence of hepatic malignancy in 451,186 UK Biobank participants of European ancestry and stratified them by carriage of C282Y and H63D variants in the HFE gene (JAMA 2020;324:2048–2057). This study has its background in exploring the clinical penetrance of HFE hemochromatosis. The most common cause of HFE hemochromatosis is C282Y homozygosity, which affects 0.5%–0.6% of individuals of northern European descent. Although studies prior to discovery of the underlying genetic defect reported a significant association of clinically diagnosed hemochromatosis with liver disease and liver cancer, there were limited contemporary data reporting liver-related outcomes, thus justifying the current population study.

RAS ID

36686

Document Type

Other

Date of Publication

2021

PubMed ID

34419460

School

School of Medical and Health Sciences

Copyright

free_to_read

Publisher

Elsevier

Identifier

John Olynyk

ORCID : 0000-0003-0417-3411

Comments

Olynyk, J. K., & Ramm, G. A. (2021). Risk of liver cancer in HFE-hemochromatosis. Gastroenterology, 161(5), 1718-1719. https://doi.org/10.1053/j.gastro.2021.08.025

Recommended Citation

Olynyk, J. K., & Ramm, G. A. (2021). Risk of liver cancer in HFE-hemochromatosis. DOI: https://doi.org/10.1053/j.gastro.2021.08.025